Prognostic and Predictive Value of NAR Score in Gastric Cancer
- PDF / 225,970 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 47 Downloads / 211 Views
ORIGINAL RESEARCH
Prognostic and Predictive Value of NAR Score in Gastric Cancer Gokhan Ucar 1 & Yusuf Acikgoz 1 & Yakup Ergun 1 & Tulay Eren 2 & Merve Dirikoc 1 & Selin Aktürk Esen 1 & Ozan Yazıcı 3 & Dogan Uncu 1 & Nuriye Yildirim Ozdemir 3 Accepted: 12 October 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Introduction Neoadjuvant treatment is a widely accepted approach for locally advanced rectum cancer. Efforts to explore a surrogate endpoint for clinical trials revealed a new prognostic scoring system which is named as neoadjuvant rectal score (NAR) in patients who received neoadjuvant treatment for rectal cancer. Material and Methods 88 patients who met inclusion criteria were included in the study. The optimal cutoff value of the NAR score was 17.6 with 71% sensitivity and 63% specificity. Patients with NAR score > 17.6 (n: 48, 54%) were defined as the highrisk group and those with NAR score ≤ 17.6 (n: 40, 56%) as the low-risk group. Result Survival analysis according to the NAR score group (low-risk vs high-risk) revealed that there was a statistically significant difference between groups regarding OS and DFS. The median OS for high-risk patients was 27.3 months (95% CI, 15.0– 39.6); it was 76.6 months (47.3–106.0) for low-risk patients (p < 0.0001). The median DFS was 15.1 months (11.8–18.4) for high-risk patients; it was 44.3 months (95% CI, 4.1–84.6) in the low-risk group (p = 0.002). Discussion As a result, we interpreted our findings as supporting data about the utility of NAR score not only as a surrogate endpoint for the clinical trial of rectal cancer but also as a prognostic marker in patients with gastric cancer who received neoadjuvant treatment. Keywords Gastric cancer . NAR score . Neoadjuvant . Prognostic . Predictive
Introduction Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death all over the world. The expected number of new cases was 1 million and death was 783.000 in 2018 worldwide [1]. According to the SEER database, the ratio of localized disease is 28%, and metastatic disease
is 36% in the USA (https://seer.cancer.gov/statfacts/html/ stomach.html). The 5-year survival rate is approximately 32% for all stages. While expected 5-year survival is 69.5% in localized disease, it is only 5.5% for metastatic disease. The expected 5-year survival rate has shown a steady increase from 1975 to 2012 which was mostly caused by newer treatment approaches including the neoadjuvant treatment approach.
* Gokhan Ucar [email protected]
Ozan Yazıcı [email protected]
Yusuf Acikgoz [email protected]
Dogan Uncu [email protected]
Yakup Ergun [email protected]
Nuriye Yildirim Ozdemir [email protected]
Tulay Eren [email protected]
1
Medical Oncology, Ankara City Hospital, Ankara, Turkey
Merve Dirikoc [email protected]
2
Medical Oncology, Yıldırım Beyazıt Dışkapı Training and Research Hospital, Ankara, Turkey
Selin Aktürk Esen [email protected]
3
Medical Oncology, Medicine F
Data Loading...
